Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure

Anne J Lee1, Peter McCluskey1,21Department of Ophthalmology, Liverpool Hospital, Liverpool, NSW, Australia; 2Faculty of Medicine, University of New South Wales, Randwick, NSW, AustraliaAbstract: Lowering IOP is the most readily modifiable risk factor to delay the development and progression of glauc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anne J Lee, Peter McCluskey
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a42a0c5bcbbc46388204de8f55402a7c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a42a0c5bcbbc46388204de8f55402a7c
record_format	dspace
spelling	oai:doaj.org-article:a42a0c5bcbbc46388204de8f55402a7c2021-12-02T00:49:20ZFixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure1177-54671177-5483https://doaj.org/article/a42a0c5bcbbc46388204de8f55402a7c2008-10-01T00:00:00Zhttp://www.dovepress.com/fixed-combination-of-topical-brimonidine-02-and-timolol-05-for-glaucom-a2359https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Anne J Lee1, Peter McCluskey1,21Department of Ophthalmology, Liverpool Hospital, Liverpool, NSW, Australia; 2Faculty of Medicine, University of New South Wales, Randwick, NSW, AustraliaAbstract: Lowering IOP is the most readily modifiable risk factor to delay the development and progression of glaucoma (POAG). The fixed combination of brimonidine tartrate 0.2% and timolol maleate 0.5% (FCBT) combines a highly selective &alpha;2-adrenergic agonist (brimonidine) with a non-selective &beta;-blocker (timolol). FCBT reduces aqueous production and enhances uveoscleral outflow. Concomitant brimonidine and timolol have additive effects on reducing intraocular pressure (IOP). Multi-center randomized control trials have documented superiority of FCBT twice daily on IOP control compared with monotherapy with the individual components, and equal efficacy compared with concomitant therapy. IOP reduction with FCBT versus fixed combination dorzolamide 2% and timolol 0.5% (FCDT) was similar in a small study. Other studies (n &gt; 293) evaluating concomitant brimonidine and timolol have shown that it is not inferior to FCDT. However, concomitant brimonidine and timolol administered twice daily was significantly less efficacious in IOP reduction than fixed combination latanoprost 0.005% and timolol 0.5% (FCLT). There are no published studies comparing FCBT with FCLT. The side effect profile for FCBT reflects that of its individual components. FCBT was generally well tolerated, with less ocular side effects than brimondine alone, but more than timolol alone. Documented systemic effects were few, although this could be confounded by selection bias. FCBT is a safe and effective IOP lowering agent for POAG and ocular hypertension.Keywords: brimonidine, timolol, combigan, glaucoma, combination, ocular hypertension Anne J LeePeter McCluskeyDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2008, Iss Issue 3, Pp 545-555 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Anne J Lee Peter McCluskey Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
description	Anne J Lee1, Peter McCluskey1,21Department of Ophthalmology, Liverpool Hospital, Liverpool, NSW, Australia; 2Faculty of Medicine, University of New South Wales, Randwick, NSW, AustraliaAbstract: Lowering IOP is the most readily modifiable risk factor to delay the development and progression of glaucoma (POAG). The fixed combination of brimonidine tartrate 0.2% and timolol maleate 0.5% (FCBT) combines a highly selective &alpha;2-adrenergic agonist (brimonidine) with a non-selective &beta;-blocker (timolol). FCBT reduces aqueous production and enhances uveoscleral outflow. Concomitant brimonidine and timolol have additive effects on reducing intraocular pressure (IOP). Multi-center randomized control trials have documented superiority of FCBT twice daily on IOP control compared with monotherapy with the individual components, and equal efficacy compared with concomitant therapy. IOP reduction with FCBT versus fixed combination dorzolamide 2% and timolol 0.5% (FCDT) was similar in a small study. Other studies (n &gt; 293) evaluating concomitant brimonidine and timolol have shown that it is not inferior to FCDT. However, concomitant brimonidine and timolol administered twice daily was significantly less efficacious in IOP reduction than fixed combination latanoprost 0.005% and timolol 0.5% (FCLT). There are no published studies comparing FCBT with FCLT. The side effect profile for FCBT reflects that of its individual components. FCBT was generally well tolerated, with less ocular side effects than brimondine alone, but more than timolol alone. Documented systemic effects were few, although this could be confounded by selection bias. FCBT is a safe and effective IOP lowering agent for POAG and ocular hypertension.Keywords: brimonidine, timolol, combigan, glaucoma, combination, ocular hypertension
format	article
author	Anne J Lee Peter McCluskey
author_facet	Anne J Lee Peter McCluskey
author_sort	Anne J Lee
title	Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
title_short	Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
title_full	Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
title_fullStr	Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
title_full_unstemmed	Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
title_sort	fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/a42a0c5bcbbc46388204de8f55402a7c
work_keys_str_mv	AT annejlee fixedcombinationoftopicalbrimonidine02andtimolol05forglaucomaanduncontrolledintraocularpressure AT petermccluskey fixedcombinationoftopicalbrimonidine02andtimolol05forglaucomaanduncontrolledintraocularpressure
_version_	1718403457866530816

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure

Ejemplares similares